Eloralintide: Risks & Legal Status
Important safety information, risks, and regulatory status
📌TL;DR
- •4 risk categories identified
- •0 high-severity risks
- •Legal status varies by country (3 countries listed)
Risk Assessment
Eloralintide has not been approved by any regulatory authority. All clinical data are from Phase 1 and Phase 2 trials. Long-term safety, rare adverse events, and outcomes beyond 48 weeks are unknown.
Nausea and fatigue are dose-dependent and can reach 64% and 46% respectively at the highest dose (9 mg). While generally mild to moderate, these may limit tolerability and adherence at higher doses.
Effects of chronic amylin receptor agonism on bone density, pancreatic function, hepatic health, and cardiovascular outcomes have not been established. The longest published treatment data are 48 weeks.
Like other anti-obesity medications, weight regain after treatment discontinuation is expected. The durability of weight loss after stopping eloralintide has not been studied.
⚠️Important Warnings
- •'Investigational drug: Eloralintide is not approved for any indication. Use only within authorized clinical trials.'
- •'Dose-dependent nausea: Nausea may affect up to 64% of patients at the 9 mg dose. Dose escalation may reduce incidence.'
- •'Pregnancy: Eloralintide has not been studied in pregnant women. Weight loss during pregnancy is not recommended.'
- •'Type 2 diabetes: Efficacy and safety in patients with type 2 diabetes have not been established (excluded from Phase 2).'
- •'Not commercially available: Eloralintide is not available through any pharmacy, compounding facility, or research supplier.'
Legal Status by Country
| Country | Status | Notes |
|---|---|---|
| United States | Investigational | Not FDA-approved. Phase 3 ENLIGHTEN program initiated with trials for obesity monotherapy and obesity with knee osteoarthritis. Developed by Eli Lilly. |
| European Union | Investigational | Not EMA-approved. Clinical trials may be active in EU member states as part of the global development program. |
| International | Investigational | Not approved in any jurisdiction. Available only through clinical trial enrollment. |
Community Risk Discussions
See how the community discusses and manages these risks in practice.
Based on 10+ community reports
View community protocolsCritical Safety Information#
Eloralintide (LY3841136) is an investigational selective amylin receptor agonist developed by Eli Lilly that has not been approved by any regulatory authority. All safety information is derived from Phase 1 and Phase 2 clinical trials involving a combined total of approximately 411 participants, with the longest treatment duration of 48 weeks. This represents a limited safety database from which to draw definitive conclusions about long-term risks.
Investigational Status Risk#
The primary risk associated with eloralintide is the inherent uncertainty of investigational drugs:
- Limited long-term data: The longest published treatment data are 48 weeks from the Phase 2 trial
- Small safety database: Approximately 411 participants across all published studies; rare adverse events occurring at rates below 1% may not yet be detected
- No post-marketing surveillance: Adverse events that emerge with broader use are unknown
- Phase 3 ongoing: The ENLIGHTEN program is enrolling but results are pending
- No regulatory review: The benefit-risk profile has not been formally assessed by the FDA or EMA
Dose-Dependent Risk Profile#
Eloralintide's adverse event profile is strongly dose-dependent:
Higher Doses (6-9 mg)#
- Nausea: up to 64%
- Fatigue: up to 46%
- GI symptoms: significantly above placebo
- Weight loss: highest (13.8-20.1%)
Lower Doses (1-3 mg)#
- Nausea and fatigue rates similar to placebo
- GI symptoms similar to placebo
- Weight loss: 9.5-10.5%
This creates a therapeutic dilemma between maximizing efficacy and minimizing adverse events that dose escalation only partially resolves.
Unknown Long-Term Effects#
The following potential risks of chronic amylin receptor agonism have not been adequately studied:
Bone Health#
- Amylin has physiological roles in bone metabolism
- Long-term effects of selective AMY1R agonism on bone mineral density are unknown
- Calcitonin (which shares the CTR receptor) affects bone resorption; eloralintide's selectivity may limit this concern
Cardiovascular Effects#
- No cardiovascular outcome trial has been conducted
- The Phase 2 trial showed improvements in cardiometabolic risk factors (blood pressure, lipids)
- However, short-term metabolic improvements do not guarantee long-term cardiovascular benefit
Pancreatic Safety#
- Amylin is co-secreted with insulin from pancreatic beta cells
- Effects of exogenous amylin agonism on beta cell function and pancreatic health over years of treatment are unknown
Hepatic Health#
- Effects on non-alcoholic fatty liver disease have not been specifically studied
- Weight loss generally improves hepatic steatosis, but direct hepatic effects of AMY1R agonism are not characterized
Weight Regain Risk#
Based on the experience with other anti-obesity medications (GLP-1 agonists, orlistat, phentermine):
- Weight regain after treatment discontinuation is expected
- No data are available on the rate or magnitude of weight regain after stopping eloralintide
- Chronic treatment is likely required for sustained weight loss, as with all current anti-obesity medications
Regulatory and Legal Status#
Eloralintide is not approved for use in any country and is not commercially available.
| Jurisdiction | Status | Key Details |
|---|---|---|
| United States (FDA) | Investigational | Phase 3 ENLIGHTEN program; developed by Eli Lilly |
| European Union (EMA) | Investigational | May be active in EU clinical trial sites |
| International | Investigational | Not available outside clinical trials |
Risk-Benefit Context#
The risk-benefit assessment for eloralintide should consider:
Potential benefits:
- Substantial weight loss (up to 20.1% in Phase 2) approaching leading incretin therapies
- Mechanistically distinct from GLP-1 agonists, offering an alternative for non-responders
- Selective AMY1R mechanism may offer improved tolerability vs non-selective amylin analogs
- Combination potential with tirzepatide for enhanced efficacy
- Improvements in cardiometabolic risk factors
Current risks and uncertainties:
- Investigational status with limited long-term data
- Dose-dependent nausea and fatigue at effective doses
- Unknown effects of chronic AMY1R agonism on bone, pancreas, and cardiovascular outcomes
- Expected weight regain after discontinuation
- Not available outside clinical trials
Medical Disclaimer#
This information is provided for educational and research purposes only. Eloralintide is an investigational drug that has not been approved for any use. It is not available for purchase or use outside of authorized clinical trials. This content does not constitute medical advice, and no individual should attempt to obtain or use eloralintide based on this information. Consult a healthcare provider for questions about obesity management.
Related Reading#
Frequently Asked Questions About Eloralintide
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.